牛牛AI助理已提取核心訊息
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced its unaudited preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made in conjunction with the company's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Illumina reported a consolidated revenue of approximately $1,115 million for Q4 2023, marking a 3% increase from Q4 2022, and a total revenue of approximately $4,497 million for the fiscal year 2023, which is a 2% decrease from the previous year. The company's core revenue also saw a 2% increase in Q4 2023 compared to the same quarter in the previous year, but experienced a 3% decline for the full fiscal year. Illumina shipped a total of 79 NovaSeq X instruments in Q4 and 352 for the...Show More
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced its unaudited preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made in conjunction with the company's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Illumina reported a consolidated revenue of approximately $1,115 million for Q4 2023, marking a 3% increase from Q4 2022, and a total revenue of approximately $4,497 million for the fiscal year 2023, which is a 2% decrease from the previous year. The company's core revenue also saw a 2% increase in Q4 2023 compared to the same quarter in the previous year, but experienced a 3% decline for the full fiscal year. Illumina shipped a total of 79 NovaSeq X instruments in Q4 and 352 for the entire year. The GAAP operating margin for Q4 was reported at approximately (15.5%) and (24.0%) for the fiscal year, while non-GAAP operating margins were 3.8% for Q4 and 5.3% for the fiscal year. Core Illumina's GAAP operating margin stood at 2.4% for Q4 and 12.3% for the fiscal year, with non-GAAP operating margins at 18.0% for Q4 and 19.8% for the fiscal year. The company plans to report its full fourth quarter and fiscal year 2023 results on February 8, 2024, after market close. The preliminary results are subject to the completion of accounting and annual audit procedures and may be adjusted.
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 公佈了截至2023年12月31日的第四季度和財年未經審計的初步財務業績。該公告是在公司於2024年1月9日參加第42屆摩根大通醫療保健年度會議時發佈的。Illumina報告稱，2023年第四季度的合併收入約爲11.15億美元，較2022年第四季度增長3％，2023財年的總收入約爲44.97億美元，比上年下降2％。與去年同期相比，該公司的核心收入在2023年第四季度也增長了2％，但整個財年下降了3％。Illumina在第四季度共出貨了79臺NovaSeq X儀器，全年共出貨了352臺儀器。據報告，第四季度的GAAP營業利潤率...展開全部
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 公佈了截至2023年12月31日的第四季度和財年未經審計的初步財務業績。該公告是在公司於2024年1月9日參加第42屆摩根大通醫療保健年度會議時發佈的。Illumina報告稱，2023年第四季度的合併收入約爲11.15億美元，較2022年第四季度增長3％，2023財年的總收入約爲44.97億美元，比上年下降2％。與去年同期相比，該公司的核心收入在2023年第四季度也增長了2％，但整個財年下降了3％。Illumina在第四季度共出貨了79臺NovaSeq X儀器，全年共出貨了352臺儀器。據報告，第四季度的GAAP營業利潤率約爲（15.5％）和（24.0％），而第四季度的非GAAP營業利潤率爲3.8％，該財年的5.3％。Core Illumina第四季度的GAAP營業利潤率爲2.4％，本財年的營業利潤率爲12.3％，第四季度的非公認會計准則營業利潤率爲18.0％，該財年的19.8％。該公司計劃在市場收盤後於2024年2月8日公佈其第四季度和2023財年的完整業績。初步結果視會計和年度審計程序的完成而定，並可能進行調整。
有用
沒用